Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2006

View Archived Issues

SOCS highlighted at a recent meeting as future drug design targets

Improvements in metabolic risk factors in HIV lipodystrophy study of EG-005

New Japanese agreement for antipruritic agent TRK-820

Syntaxin and Allergan to develop novel clostridial endopeptidase-based compounds

Roswell Park Cancer Institute receives grant to develop aspergillus vaccine

CUV-1647 studied in phase II trial for erythropoietic protoporphyria

Roche requests reexamination of CHMP negative opinion for Tarceva

Major tumor shrinkage observed in study of AS-1411

Arpida completes enrollment in phase III study of iclaprim in cSSSI

ICX-PRO studied in phase II trial for diabetic foot ulcers

Cardioprotective effects of olive oil components

Clinical data indicate that aspirin and clopidogrel do not interact with TGN-255

Spectrum offers Q2 overview

Abbott reports on novel TRPV1 antagonists with efficacy against inflammatory pain

EUK-189 produces encouraging results for treatment of radiation dermatitis

European orphan drug status for TRO-19622 in ALS

Recent Meiji Dairies and NeuroMed patents disclose novel analgesic agents

Virax files to begin phase I/IIa study of VIR-201 HIV vaccine in S. Africa

Pivotal Acapodene studies recommended to continue

New agents for treating neurological disorders disclosed in recent patent literature

End-of-review meeting for indiplon IR NDA

Ajinomoto patents novel coagulation factor Xa inhibitors

Phase III topline results for alvimopan in opioid-induced bowel dysfunction

The immunosuppressive effects of PARP inhibition enhance cardiac graft survival

Novel PI3Kdelta inhibitors reported in recent Ono patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...